From: Circulating miR-200c and miR-141 and outcomes in patients with breast cancer
Characteristic | Patients | Controls | |
---|---|---|---|
n = 57 (%) | n = 20 (%) | ||
Age (years, mean ± SD) | 55.4 ± 12.8 | 54.8 ± 14.3 | 0.853* |
<55 | 28 (49) | 12 (60) | 0.48** |
≥55 | 29 (51) | 8 (40) | |
Menopause | |||
Pre-menopausal | 24 (42.1) | N/A | |
Post-menopausal | 33 (57.9) | N/A | |
Histology | |||
Ductal | 50 (87.7) | ||
Lobular | 5 (8.8) | ||
Other | 2 (3.5) | ||
Histological grade | |||
1 | 7 (12.3) | ||
2 | 25 (43.9) | ||
3 | 23 (40.4) | ||
TNM Stage | |||
I | 14 (24.6) | ||
II | 13 (22.8) | ||
III | 17 (29.8) | ||
IV | 13 (22.8) | ||
Lymph nodes involved | |||
No | 20 (35.1) | ||
Yes | 37 (64.9) | ||
Hormonal Receptors | |||
Positive | 42 (73.7) | ||
Negative | 14 (24.6) | ||
HER2 | |||
Positive | 14 (24.6 ) | ||
Negative | 42 (73.7 ) | ||
MIB1 | |||
<25% | 40 (70.2) | ||
>25% | 14 (24.6) | ||
Type | |||
Luminal | 32 (56.1) | ||
HER2 | 14 (24.6) | ||
Triple negative | 10 (17.5) | ||
R0 | 28 (49.1) | ||
R2 | 29 (50.9) |